IVF Market Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts

The global IVF market was estimated at US$ 28.31 billion in 2025 and is expected to reach US$ 49.12 billion by 2033, growing at a CAGR of 7.13% during 2025-2033. This strong market growth is driven by rising cases of infertility worldwide, which are brought on by factors such as delayed family planning, changes in lifestyle, and environmental influences. Advancements in assisted reproductive technologies, including genetic screening, cryopreservation, donor programs, and enhanced laboratory techniques, have remarkably improved the success rates of IVF, boosting patient confidence and the adoption of the technique.

In-vitro fertilization is an assisted reproductive technology used to help individuals and couples conceive when natural conception is difficult or not possible. The process involves retrieving mature eggs from the ovaries, fertilizing them with sperm in a laboratory setting, and then transferring the resulting embryo into the uterus. IVF may also involve supplementary techniques such as ICSI, egg or sperm donation, genetic screening, and embryo freezing. It is mainly used for tubal problems, low sperm count, endometriosis, ovulation disorders, or unexplained infertility. IVF also supports family planning for single parents by choice, LGBTQ+ couples, and individuals preserving fertility before medical treatments.

Surging infertility rates, advances in medical technology, and increasing social acceptance of assisted reproduction contribute to the growing popularity of IVF worldwide. Most countries have increased fertility clinics, improved success rates, and treatments that have become more financially accessible. Delayed parenthood, lifestyle factors, and growing awareness of reproductive health further accelerate demand. Besides being a medical intervention, IVF is considered a pathway to parenthood for different kinds of families around the world.

Top Manufacturers

FUJIFILM Holdings Corporation

Headquarters: Japan
Founded: 1934
Fujifilm Holdings Corp, also known as Fujifilm, is engaged in designing, developing, and marketing products related to three primary businesses: healthcare solutions, material solutions, and imaging systems. The product portfolio consists of medical devices, semiconductor materials, instant cameras, color film and chemicals, photofinishing equipment, inkjet printheads, office solutions, and imaging equipment. The company's products cater to industries such as healthcare, electronics, and business communications, with solutions regarding medical diagnostics, industrial effectiveness, and digital transformation. The company sells its products through a network of channel partners and distribution networks. It has business operations in the Americas, Europe, Africa, and Asia-Pacific.

Hamilton Thorne Ltd.

Headquarters: Unites States
Founded: 1986
Hamilton Thorne Ltd. is a leading biotechnology and precision instrumentation company that develops advanced tools for assisted reproductive technologies, or ART, including IVF, animal breeding, and research applications. The company's headquarters are in Beverly, Massachusetts. It offers a range of products: laser systems, imaging solutions, sperm analysis equipment, and laboratory consumables-each employed in fertility clinics, research laboratories, and by pharmaceutical organizations around the world. Hamilton Thorne is well-known for its innovative CASA systems and ZILOS-tk laser technology that greatly enhance accuracy and efficiency in embryo handling, sperm assessment, and micromanipulation procedures. Quality, regulatory compliance, and continuous innovation are focus areas for this organization in an effort to support improved reproductive outcomes and scientific advancement.

Vitrolife AB

Headquarters: Sweden
Founded: 1994
Vitrolife AB develops, produces and markets laboratory products. The company offers products like oocyte retrieval needles, sperm processing, culture media, culture oil, additional culture media, micromanipulation solutions, vitrolife labware and micromanipulation pipettes. It also offers products which include a time-lapse system, vitrification, slow freezing, octax laser and imaging system, log and guard and embryo biopsy. The company sells its products under the brand name, Vitrolife. Vitrolife has products for the preparation, cultivation, preservation and support of human cells, tissues and organs. The company supplies media and related disposables used by laboratories and hospitals performing fertility treatment and other therapies. It offers optimized solutions for organ, tissue and cell preservation concerning transplantation. The company operates in Sweden and the US. Vitrolife is headquartered in Gothenburg, Vastra Gotaland, Sweden.

Thermo Fisher Scientific, Inc.

Founded: 2006
Headquarters: United States of America
Thermo Fisher Scientific Inc. is a major supplier of a broad range of analytical instruments, life sciences solutions, and specialty diagnostics. Product offerings in its portfolio include laboratory essentials, advanced instruments for clinical applications, chromatography and mass spectrometry systems, and molecular biology instruments. Thermo Fisher customers include pharmaceutical and biotechnology companies, research institutions, universities, and government agencies. The company sells its products under several brands: Thermo Scientific, Applied Biosystems, and Fisher Scientific, among others, through direct sales, customer service, e-commerce sites, and third-party distributors.

Bayer AG

Establishment: 1863
Headquarters: Leverkusen, Germany
Bayer AG is a leading global life science company specialized in health and nutrition. The three main fields of activity under the Bayer AG umbrella include Pharmaceuticals, Consumer Health, and Crop Science. Among these, the Crop Science division is one of the top companies in the agriculture industry, dealing with seeds, crop protection, and pest control other than agricultural applications. Under the Crop Protection and Seeds operating segment, Bayer combines a broad portfolio of high-value seeds with extensive offerings in Crop Protection to provide resource-conserving agricultural practices. As of December 31, 2022, Bayer Group comprises 354 consolidated companies in more than 83 countries and employs approximately 101,369 people all over the world.

Product Launches within the IVF Market

Merck & Co., Inc.

Sept 2023, Merck, a leading science and technology company, is launching an extensive Fertility Benefit program in October 2023 that will provide employees with financial support for fertility treatments. The program will be launched in eight markets, specifically Germany, the United Kingdom, Switzerland, China, India, Taiwan, Brazil, and Mexico. This adds to the existing offerings Merck provides for employees in the United States, Canada, and Japan. A further roll-out of the offering to Merck employees in additional countries is expected to begin next year.

Fortis Healthcare

Apr 2025, Fortis Healthcare Launches ‘Fortis Institute of Genomic Medicine’ Ushering a New Era in Precision Medicine. Fortis Healthcare launched ‘Fortis Institute of Genomic Medicines’, a pioneering center dedicated to harnessing the power of genomic science to transform patient care across India. Backed by Fortis’ advanced clinical ecosystem and Agilus Diagnostics’ extensive national footprint, the institute will bring together a multi-disciplinary team of medical experts including Molecular Hematology, Oncology, Neurology, Pediatrics, Pathology, Genomic scientists alongwith bioinformaticians and AI (artificial intelligence) engineers.

SWOT Analysis of the Company

Esco Medical / Esco Micro Pte. Ltd.

Strengths: specialization in advanced IVF lab equipment, strong product innovation, and global clinical trust.
Esco Medical shows remarkable strengths in the IVF market: it specializes in advanced IVF laboratory equipment, has strong product innovation, and enjoys global clinical trust. The company offers highly sophisticated solutions aimed at enhancing embryo viability and improving clinical outcomes, such as time-lapse incubators, laminar flow workstations, and embryo culture systems. With its strong focus on precision engineering, biological safety, and environmental stability, Esco Medical positions itself as a preferred partner for fertility clinics and research institutions. Its devices are compliant with strict regulatory standards, such as ISO and CE certifications, further reinforcing credibility and market acceptance. Continuous investment in R&D and strategic collaboration with scientific communities further fuels innovation. This assists Esco Medical in gaining from the increasing demand for high-performance embryology technologies, as IVF clinics seek optimized culture environments and automation.

Ferring Pharmaceuticals

Strengths include leading portfolio of fertility-focused therapeutics, global brand recognition, deep clinical expertise.

Ferring Pharmaceuticals continues to enjoy certain key advantages in the IVF market, especially on account of its leading portfolio of fertility-focused therapeutics, global brand recognition, and deep clinical expertise. The company is well-acknowledged for developing hormone-based therapies that are vital for ovarian stimulation, embryo implantation, and reproductive endocrinology. Products such as gonadotropins, progesterone supplements, and personalized dosing solutions reinforce Ferring's position as a significant provider of IVF treatment protocols. Longstanding collaborations with reproductive specialists, clinical institutes, and scientific organizations have strengthened product credibility and clinical adoption. Ferring is established in over 100 countries around the world, benefitting from wide access to various fertility markets. Further investment in research, real-world evidence studies, and innovation including personalized medicine and digital fertility platforms strengthens its leading position in assisted reproduction. Its strong patient-centric approach and comprehensive treatment support programs further elevate its standing in the IVF sector.

Recent Development in the In Vitro Fertilization (IVF) Market

The Cooper Companies, Inc.

Nov. 01, 2023, CooperCompanies (Nasdaq: COO), announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price was $300 million with $200 million paid at closing and the remaining $100 million to be paid in two $50 million annual installments. “This acquisition is a fantastic strategic fit for CooperSurgical,” said Al White, President and CEO of CooperCompanies. “The acquired products are highly synergistic with CooperSurgical’s existing portfolio of medical devices and strengthen CooperSurgical’s position as a leading global fertility and women’s health company.”

Cook Medical (Cook Group)

Oct 2024, Cook Medical announces the availability of the NestVT Vitrification Device in the United States. NestVT is a safe and secure solution for the vitrification, cryo-storage, and relocation of embryos and oocytes. In conjunction with this new product introduction, Cook is evolving to be a trusted IVF partner by providing simulation training and education classes to support all aspects of IVF.

Sustainability Goal

Kitazato Corporation

Kitazato Corporation integrates sustainability into its IVF operations through resource-efficient manufacturing, environmentally responsible product design, and ethical reproductive innovation. The company is committed to using durable, high-quality medical materials that reduce waste by extending product life cycles and minimizing environmental impact associated with single-use, disposable laboratory consumables. Similarly, Kitazato optimizes energy usage in its production facilities, investing in greener, low-impact manufacturing processes. Beyond environmental responsibility, the company focuses on safety in reproductive practices, supporting evidence-based medicine, ethical sourcing, and transparency in clinical applications. The cryopreservation systems and embryo handling tools are designed to support higher success rates while reducing the need for repeated procedures and lowering clinical waste indirectly. Kitazato looks to support sustainable growth within reproductive medicine by combining scientific excellence with environmentally conscious business practices.

Boston IVF

Boston IVF incorporates sustainability into its clinical and operational framework through key priorities in energy-efficient laboratory environments, reduced medical waste, and responsible patient care. The organization actively incorporates green initiatives into its operations, including optimized HVAC systems, smart lighting, and energy-saving workstations to reduce the impact of operating high-intensity IVF laboratories. Boston IVF also focuses on reducing disposable plastic usage with extensive recycling programs and careful evaluation of consumable materials. Clinically, the organization fosters ethical treatment pathways, personalized care, and minimally invasive approaches that enable a reduction in avoidable medication and repeated procedures. Boston IVF supports continued research, education, and community partnerships toward fertility advancements while fostering equity in access to reproductive health. It is through these efforts, in alignment with health outcomes and environmentally conscious operations, that Boston IVF strives to build a sustainable, patient-centered future for fertility treatment.

Market Segmentation

IVF Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - IVF Market

FUJIFILM Holdings Corporation

Overview

• Company History and Mission
• Business Model and Operations

Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

• FUJIFILM Holdings Corporation
• Hamilton Thorne Ltd.
• Vitrolife AB
• Thermo Fisher Scientific, Inc.
• Bayer AG
• Merck & Co., Inc.
• The Cooper Companies, Inc.
• Fortis Healthcare
• Cook Medical (Cook Group)
• Irvine Scientific (a FUJIFILM subsidiary)
• Genea Biomedx
• Esco Medical / Esco Micro Pte. Ltd.
• Ferring Pharmaceuticals
• Kitazato Corporation
• Boston IVF (service provider)
• EMD Serono (Merck KGaA)
• Labotect GmbH
• Olympus LifeSciences
• Bloom Fertility & Healthcare
• Nova IVF Fertility